Please assess the completion status of the following clinical trial:

Trial Title: First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years to ≤ 75 years.~* Epithelial ovarian cancer with pathology confirmed stage IIIc or IV, expect for lymph node metastasis alone~* Optimal cytoreductive surgery, including hysterectomy, bilateral salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a residual disease no more than 1cm~* Available to receive intraperitoneal chemotherapy 5-10 days postoperative, or no more than postoperative 14 days for those with bowel resection.~* ECOG performance 0-2.~* No more than 3 cycles of chemotherapy prior to surgery.~* Laboratory testing within 7 days of registration: hematopoietic: absolute neutrophil count greater than 1,500/mm3; Platelet count greater than 100,000/mm3. Hepatic: bilirubin less than 1.25 times upper limit of normal (ULN); Bilirubin \< 2.0, SGPT less than 2 times ULN. Renal: creatinine less than 1.6 mg/dL, OR creatinine clearance greater than 40 mL/min.~* Comply with intraperitoneal chemotherapy and follow-up.~* Written informed consent.~Exclusion Criteria:~* Low-malignant potential ovarian tumor.~* Laboratory testing insufficiency. Hemoglobin \< 10 g/dL. Renal insufficiency with serum creatinine \> 1.6.~* Bone marrow dysfunction: absolute neutrophil count less than 1,500/mm3; Platelet count less than 80,000/mm3.~* Active infection.~* Clinically significant gastrointestinal abnormalities.~* Active coronary artery disease, cerebrovascular disease, restrictive or obstructive pulmonary disease, or congestive heart failure.~* Other condition that could interfere with provision of informed consent, compliance to study procedures, or follow-up.~* Prior invasive malignancies within the last 5 years showing activity of disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Regimen B, PEip and TCiv therapy (Type: EXPERIMENTAL): Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
- Regimen A: Standard TCiv therapy (Type: ACTIVE_COMPARATOR): IV paclitaxel plus carboplatin or docetaxel plus carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).